NervGen Pharma Corp.

OTCPK:NGEN.F Stock Report

Market Cap: US$112.7m

NervGen Pharma Valuation

Is NGEN.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NGEN.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate NGEN.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate NGEN.F's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NGEN.F?

Key metric: As NGEN.F is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for NGEN.F. This is calculated by dividing NGEN.F's market cap by their current book value.
What is NGEN.F's PB Ratio?
PB Ratio19.4x
BookCA$9.18m
Market CapCA$157.38m

Price to Book Ratio vs Peers

How does NGEN.F's PB Ratio compare to its peers?

The above table shows the PB ratio for NGEN.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average79x
DERM Journey Medical
9.9x79.9%US$108.4m
TELO Telomir Pharmaceuticals
299.4x-67.2%US$124.4m
MIST Milestone Pharmaceuticals
5.1x63.6%US$123.2m
RLMD Relmada Therapeutics
1.7x-11.2%US$86.0m
NGEN.F NervGen Pharma
19.4xn/aUS$157.4m

Price-To-Book vs Peers: NGEN.F is good value based on its Price-To-Book Ratio (19.4x) compared to the peer average (79x).

Price to Book Ratio vs Industry

How does NGEN.F's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.1xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.39m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.92m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.50m
NGEN.F 19.4xIndustry Avg. 1.7xNo. of Companies23PB012345+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: NGEN.F is expensive based on its Price-To-Book Ratio (19.4x) compared to the US Pharmaceuticals industry average (1.7x).

Price to Book Ratio vs Fair Ratio

What is NGEN.F's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NGEN.F PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio19.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate NGEN.F's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NGEN.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.79
US$3.22
+80.0%
11.1%US$3.58US$2.86n/a2
Nov ’25US$1.83
US$3.32
+81.3%
11.1%US$3.69US$2.95n/a2
Oct ’25US$1.82
US$3.32
+82.8%
11.1%US$3.69US$2.95n/a2
Sep ’25US$2.08
US$3.31
+59.0%
11.1%US$3.67US$2.94n/a2
Aug ’25US$2.10
US$3.31
+57.8%
11.1%US$3.67US$2.94n/a2
Jul ’25US$2.16
US$3.27
+51.3%
11.1%US$3.63US$2.91n/a2
Jun ’25US$1.43
US$3.27
+128.6%
11.1%US$3.63US$2.91n/a2
May ’25US$1.48
US$3.27
+120.8%
11.1%US$3.63US$2.91n/a2
May ’24US$1.17
US$3.95
+239.1%
14.3%US$4.52US$3.39US$1.482
Apr ’24US$1.23
US$3.95
+220.4%
14.3%US$4.52US$3.39US$1.602
Mar ’24US$1.38
US$3.95
+186.3%
14.3%US$4.52US$3.39US$2.502
Feb ’24US$1.68
US$3.95
+135.2%
14.3%US$4.52US$3.39US$2.182
Jan ’24US$1.19
US$3.95
+232.1%
14.3%US$4.52US$3.39US$2.042
Dec ’23US$1.39
US$3.95
+183.4%
14.3%US$4.52US$3.39US$1.302
Nov ’23US$1.37
US$3.85
+181.2%
14.3%US$4.40US$3.30US$1.362

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.86

7D

-5.2%

1Y

8.0%

Teva Pharmaceutical Industries

US$19.3b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$17.08

7D

2.0%

1Y

80.5%

Collegium Pharmaceutical

US$967.5m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.41

7D

0.5%

1Y

17.1%